

# Study of Lipoprotein-associated Phospholipase A2 and Carotid Intima Media Thickness as Markers of Increase Cardiovascular Risk

Davendra Kumar<sup>1</sup>, Ajay Kumar Mishra<sup>2</sup>, Mehboob Subhani Siddiqui<sup>1</sup>, Almas Qureshi<sup>3</sup>

## ABSTRACT

**Introduction:** Emerging risk markers that have demonstrated effectiveness in predicting risk for future cardiovascular disease events are carotid artery intima-media thickness (CIMT) and lipoprotein-associated phospholipase A<sub>2</sub>. The aim of our study was to compare Lp-PLA<sub>2</sub> activity and CIMT in patients with risk factors of cardiovascular diseases.

**Material and Methods:** This case-control study included adult subjects with risk factors of cardiovascular diseases as cases and healthy age and gender matched subjects as controls. LP-PLA<sub>2</sub> activity was measured with ELISA method and CIMT measurements were made just before the bifurcation of common carotid artery by using B-mode ultrasound. Univariate and multivariate analysis was performed. A two-tailed P value <0.05 was considered statistically significant.

**Results:** A total of 70 cases and 70 controls were enrolled in this study. Multivariable stepwise regression analysis revealed glycosylated hemoglobin, and non-HDL cholesterol as independent predictors of CIMT. Lp-PLA<sub>2</sub> activity had no correlation with age, BMI, systolic blood pressure, diastolic blood pressure, lipid profile, serum uric acid, and CIMT.

**Conclusion:** The results from the present study reveal that Lp-PLA<sub>2</sub> activity increases with increment of number of cardiovascular risk factors. There was no relationship observed in predicting CIMT and Lp-PLA<sub>2</sub> activity

**Keywords:** Cardiovascular risk factors, Markers, Carotid intima media thickness, Lipoprotein-associated Phospholipase A<sub>2</sub>

## INTRODUCTION

Although prevalence of conventional risk factors such as smoking, hypertension, and hypercholesterolemia is not higher in South Asians than in other ethnic groups, yet, it is seen that some risk factors for atherosclerosis are particularly prevalent among them, including high triglyceride concentration, increased level of total cholesterol to high-density lipoprotein cholesterol ratio, type-2 diabetes mellitus and central or visceral obesity.<sup>1-3</sup> Two emerging risk markers that have demonstrated effectiveness in predicting risk for future cardiovascular disease events are carotid artery intima-media thickness (CIMT) and lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>). It has been well established that CIMT is independently associated with CHD, and a consensus statement from the American Society of Echocardiography concludes that CIMT represents subclinical vascular disease, a marker of coronary heart disease (CHD).<sup>4-7</sup> Correlation between Lp-PLA<sub>2</sub> levels and traditional cardiovascular risk factors have been shown in several studies.<sup>8-10</sup> The aim of our study was to compare Lp-PLA<sub>2</sub> activity and CIMT in patients with risk factors of cardiovascular diseases.

## MATERIAL AND METHODS

This case-control study was performed at our tertiary care

centre from February 2014 to August 2015 after approval from ethics committee. This study included adults aged >40 years of either sex, attending department of general medicine at our tertiary care centre. 70 consecutive subjects with risk factors of cardiovascular diseases were selected as cases and equal number of healthy age and gender matched subjects were included as controls. Patients with history of any cardiovascular events were excluded from the study.

After taking the informed consent, a detailed history and physical examination was conducted. When possible, data were obtained directly from patients using the standardized data collection instruments as patient's proforma on lifestyle factors, current medication use, and medical history. Briefly, subjects were categorized into current smokers, ex-smokers, and never smokers and current alcohol consumers, ex-consumers, or non-consumers. When the patient was unable to provide answers, a proxy knowledgeable about the patient's history was interviewed.

These patients were then subjected to laboratory investigations including lipid profile, glycosylated hemoglobin, and Lp-PLA<sub>2</sub> activity. LP-PLA<sub>2</sub> activity was measured with ELISA method by Raybiotech Inc. USA. The level of Lp-PLA<sub>2</sub> activity was expressed as nmol/min/ml.

CIMT measurements were made just before the bifurcation of common carotid artery by using B-mode ultrasound (carotid duplex scanning with a 7.5 MHz linear superficial array probe in B-mode). Maximal and mean CIMT were defined as the greatest and mean values, respectively, of CIMT measured from 3 contiguous sites at 1-cm intervals. Patients were then classified on the basis of a normal (<1 mm) or an abnormal ( $\geq 1$  mm) CIMT. Coronary heart disease risk at 10 years in percent was calculated with the help of the Framingham Risk Score.

## STATISTICAL ANALYSIS

The statistical analysis was done using SPSS (statistical Package for social sciences) Version 20.0 statistical analysis software. Parametric data have been presented as mean  $\pm$  SD. Parametric data have been evaluated using Student "t"-test. Correlation coefficients were computed for the association of age, cardiovascular risk factors, and CIMT with Lp-PLA<sub>2</sub>.

<sup>1</sup>Professor, <sup>2</sup>Associate Professor, <sup>3</sup>Senior Resident, Department of Medicine, Era's Lucknow Medical College, Lucknow, Uttar Pradesh, India

**Corresponding author:** Dr. Ajay Kumar Mishra, Department of Medicine, Era's Lucknow Medical College, Lucknow, UP, India

**How to cite this article:** Davendra Kumar, Ajay Kumar Mishra, Mehboob Subhani Siddiqui, Almas Qureshi. Study of lipoprotein-associated phospholipase A2 and carotid intima media thickness as markers of increase cardiovascular risk. International Journal of Contemporary Medical Research 2017;4 (5):1083-1085.

Multiple linear regression analysis was used to evaluate the contribution of independent factors. A two-tailed P value <0.05 was considered statistically significant.

## RESULTS

A total of 70 cases and 70 controls were enrolled in this study and subsequently evaluated. Baseline characteristic of all cases and controls by gender are presented in table 1. The mean age (years) of the cases and controls was  $54.80 \pm 8.09$  and  $55.12 \pm 12$  respectively. Female to male ratio in cases and controls was 1:1.8 and 1:2.04 respectively.

Among 70 cases, the most common cardiovascular risk factor observed was diabetes mellitus in 30 (42.9%) cases, followed by Hypertension 26 (37.1%), Hyperuricemia 12 (17.1%), Hypercholesterolemia 11 (15.7%), and Obesity 4 (5.7%). History of Smoking and alcohol use was recorded in 51 (72.8%), and 53 (75.7%) cases.

The mean LPPLA<sub>2</sub> activity (nmol/min/ml) in cases and controls were  $737.48 \pm 244.24$  vs.  $556.16 \pm 29.35$  nmol/min/ml respectively. We observed that majority of the cases (64/70) were considered at elevated risk according to the  $>556.16$  nmol/min/ml (mean LpPLA<sub>2</sub> in controls) cut point for LPPLA<sub>2</sub> activity. We also observed higher CIMT in cases as compared to the controls subjects. ( $0.74 \pm 0.18$ mm vs.  $0.53 \pm 0.04$ mm, p <0.001). Comparison among groups showed no significant difference in Lp-PLA<sub>2</sub> and CIMT where cases with 3 or more risk factor were compared with those <3 risk factors, ( $752.71 \pm 265$  vs.  $722.25 \pm 223$ , p< 0.60) ( $0.79 \pm 0.17$  vs.  $0.73 \pm 0.11$ , P <0.059). Although not statistically significant, those with intermediate and high risk Framingham risk score (FRS) (i.e. >10) had higher mean LP PLA<sub>2</sub> activity and mean CIMT in comparison with Framingham risk score (FRS) of <10 ( $751.05 \pm 226.38$  vs  $723.91 \pm 222.98$ , p<0.77) and ( $0.76 \pm 0.18$  vs  $0.75 \pm 0.12$ , p<0.11). Univariate analysis of mean LP PLA<sub>2</sub> among subgroups: hypertensive, non hypertensive (OR=0.98; 95% CI 0.11–0.89; p<0.23); diabetics, non diabetics (OR=0.73; 95% CI 0.13–3.89; p<1.0); and smokers, non-smokers (OR=1.28; 95% CI 0.21–7.59; p<1.0) showed no significant correlation.

Multivariable stepwise regression analysis revealed glycosylated hemoglobin, and non-HDL cholesterol as independent predictors of CIMT (Table 2). Lp-PLA<sub>2</sub> activity had no correlation with age, BMI, systolic blood pressure, diastolic blood pressure, lipid profile, serum uric acid, and CIMT (Table-3).

## DISCUSSION

In numerous studies, an independent association between Lp-PLA<sub>2</sub> concentrations and an increased risk of cardiovascular events has been observed in individuals with varying degrees of baseline risk.<sup>11-14</sup>

In the present study, we observed that the mean Lp-PLA<sub>2</sub> activity was higher in subjects with cardiovascular risk factors as compared to controls. There was a rise in Lp-PLA<sub>2</sub> activity with an increment of number of cardiovascular risk factors. This observation was in accordance to an earlier study in Asian population. Gong H et al observed that Lp-PLA<sub>2</sub> activity was significantly increased in Metabolic syndrome subgroups when compared with Controls and there was a linear rise in Lp-PLA<sub>2</sub> activity with an increment of number of metabolic syndrome components.<sup>15</sup>

| variables                              | Case            | Controls        |
|--|-----------------|-----------------|
| Number                                 | 70              | 70              |
| Age (years)                            | $54 \pm 8$      | $54 \pm 9$      |
| Sex (male/female)                      | 45/25           | 46/23           |
| BMI (kg/m <sup>2</sup> )               | $23 \pm 3$      | $22 \pm 2$      |
| SBP (mmHg)                             | $140 \pm 12$    | $120 \pm 9$     |
| DBP (mmHg)                             | $99 \pm 10$     | $72 \pm 7$      |
| HbA1c (%)                              | $6.7 \pm 1.2$   | $4.7 \pm 0.4$   |
| FBS (mg/dl)                            | $148 \pm 81$    | $96 \pm 18$     |
| PPBS (mg/dl)                           | $204 \pm 99$    | $104 \pm 9$     |
| Mean CIMT (mm)                         | $0.76 \pm 0.15$ | $0.53 \pm 0.04$ |
| Mean Lp-PLA <sub>2</sub> (nmol/min/ml) | $737 \pm 224$   | $556 \pm 29$    |
| Cholesterol (mg/dl)                    | $179 \pm 43$    | $123 \pm 14$    |
| Non-HDL (mg/dl)                        | $135 \pm 44$    | $72 \pm 15$     |
| HDL (mg/dl)                            | $44 \pm 6$      | $51 \pm 6$      |
| Triglycerides (mg/dl)                  | $176 \pm 26$    | $142 \pm 20$    |
| Uric acid (mg/dl)                      | $6 \pm 1$       | $5 \pm 1$       |

Table-1: Baseline characteristics of cases and controls

| Variables                | Lp-PLA <sub>2</sub> |       |          |       |
|--------------------------|---------------------|-------|----------|-------|
|                          | simple              |       | multiple |       |
|                          | r                   | p     | $\beta$  | p     |
| Age (years)              | -0.025              | 0.84  | -0.14    | 0.89  |
| Sex                      | 0.116               | 0.341 | -1.1     | 0.276 |
| BMI (kg/m <sup>2</sup> ) | 0.119               | 0.328 | 0.83     | 0.409 |
| SBP (mmHg)               | 0.016               | 0.896 | 0.64     | 0.519 |
| DBP (mmHg)               | -0.034              | 0.778 | -0.77    | 0.444 |
| HbA1c (%)                | -0.035              | 0.771 | -0.88    | 0.378 |
| FBS (mg/dl)              | -0.087              | 0.474 | -0.66    | 0.512 |
| PPBS (mg/dl)             | 0.128               | 0.29  | 1.36     | 0.179 |
| Cholesterol (mg/dl)      | 0.072               | 0.552 | 0.93     | 0.352 |
| Non-HDL (mg/dl)          | 0.082               | 0.549 | 0.13     | 0.372 |
| HDL (mg/dl)              | -0.090              | 0.457 | -0.43    | 0.666 |
| Triglycerides (mg/dl)    | -0.061              | 0.617 | -1.91    | 0.06  |
| S.Uric acid (mg/dl)      | 0.189               | 0.117 | 0.94     | 0.349 |
| Mean CIMT (mm)           | 0.070               | 0.565 | 0.03     | 0.974 |
| FRS                      | -0.057              | 0.639 | -0.44    | 0.66  |

Table-2: Linear regression analysis of variables correlated with Lp-PLA<sub>2</sub> in cases

|                                   | CIMT   |        |          |        |
|-----------------------------------|--------|--------|----------|--------|
|                                   | simple |        | multiple |        |
|                                   | r      | p      | $\beta$  | p      |
| Age (years)                       | 0.92   | 0.44   | 0.057    | 0.679  |
| Sex                               | 0.136  | 0.26   | 0.236    | 0.144  |
| BMI (kg/m <sup>2</sup> )          | 0.239  | 0.047* | 0.06     | 0.634  |
| SBP (mmHg)                        | -0.224 | 0.062  | -0.026   | 0.826  |
| DBP (mmHg)                        | 0.355  | 0.003* | 0.144    | 0.279  |
| HbA1c (%)                         | 0.473  | 0.001* | 0.502    | 0.02*  |
| FBS (mg/dl)                       | 0.409  | 0.001* | 0.174    | 0.598  |
| PPBS (mg/dl)                      | -0.383 | 0.001* | -0.274   | 0.468  |
| Cholesterol (mg/dl)               | 0.377  | 0.001* | 0.747    | 0.436  |
| Non-HDL (mg/dl)                   | 0.368  | 0.002* | 0.332    | 0.034* |
| HDL (mg/dl)                       | 0.007  | 0.952  | 0.074    | 0.581  |
| Triglycerides (mg/dl)             | 0.314  | 0.008* | 0.115    | 0.409  |
| Uric acid (mg/dl)                 | -0.028 | 0.816  | -0.264   | 0.048* |
| Lp-PLA <sub>2</sub> (nmol/min/ml) | 0.07   | 0.565  | -0.03    | 0.788  |
| FRS                               | -0.196 | 0.104  | -0.217   | 0.145  |

\*p<0.05

Table-3: Linear regression analysis of variables correlated with CIMT in cases

In contrast to the previous studies, the current study found elevated CIMT in 11% (6) cases. Salonen et al. found that in 1,200 Finnish men (a population with high incidence morbidity and mortality from CHD), 20% had elevated CIMT.<sup>16</sup> The Rotterdam study, a prospective cohort study that examined over >7,000 men and women >55 years of age, reported 25% subjects had elevated CIMT.<sup>17</sup> In another study that utilized the 75th percentile criteria for elevated CIMT examined middle-aged (mean 47 years) firefighters. In a sample size of 50 subjects, 27 (54%) were shown to have elevated CIMT.<sup>18</sup> Reason for this is due to small sample size and difference in the cohort age in our study in comparison to these studies.

The results of the present study revealed no relationship in predicting CIMT and Lp-PLA<sub>2</sub> activity. These findings support several clinical studies which suggested that premature coronary atherosclerosis as well as carotid intima-media thickness plasma was not influenced by Lp-PLA<sub>2</sub> activity. Campo et al. examined the relationship between CIMT and Lp-PLA<sub>2</sub> activity in 190 Sicilian middle-aged subjects and found no relationship between these measures.<sup>19</sup> Kiortsis et al. examined the relationship between CIMT and Lp-PLA<sub>2</sub> mass and activity in 100 subjects with known dyslipidemia. Like Campos et al they found no relation between CIMT and Lp-PLA<sub>2</sub>.<sup>20</sup>

## CONCLUSION

In conclusion, the results from the present study reveal that Lp-PLA<sub>2</sub> activity increases with increment of number of cardiovascular risk factors. There was no relationship observed in predicting CIMT and Lp-PLA<sub>2</sub> activity. The major limitation of this study was that Lp-PLA2 mass was not examined, which appears to demonstrate the more potent relationship. The results of this study are based on single measurements of circulating Lp-PLA<sub>2</sub>, which may not reflect the true activity of Lp-PLA<sub>2</sub> over time in atherosclerotic plaques.<sup>15</sup>

## REFERENCES

- Ghosh A, Bose K, Das Chaudhuri AB. Association of food patterns, central obesity measures and metabolic risk factors for coronary heart disease (CHD) in middle aged Bengalee Hindu men, Calcutta, India. *Asia Pac J Clin Nutr.* 2003;12:166e171.
- Guha S, Ghosh A, Chatterjee N, et al. Risk factors for coronary heart disease in Indians: a case-control study from eastern India. *Indian Heart J.* 2005;57:738e 740.
- Ghosh A. Factor analysis of risk variables associated with metabolic syndrome in Asian Indian adolescents. *Am J Hum Biol.* 2007a;19:34e40.
- Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. *Am J Epidemiol.* 1997;146:483-94.
- Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. *Circulation.* 1990;82:1230-42.
- Rosvall M, Janzon L, Berglund G, et al. Incident coronary events and case fatality in relation to common carotid intima-media thickness. *J Intern Med.* 2005;257:430-7.
- Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. *J Am Soc Echocardiogr.* 2008;21:93-111.
- Grundy SM, Pasternak R, Greenland P, et al. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *J Am Coll Cardiol.* 1999;34:1348-59.
- Thompson A, Gao P, Orfei L et al. "Lipoprotein-associated phospholipase A<sub>2</sub> and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies." *The Lancet.* 2010;375:1536-1544.
- Vittos O, Toana B, Vittos A, and Moldoveanu E. "Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker." *Biomarkers.* 2012;17,289-302.
- Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. *Biochim Biophys Acta.* 2009; 1791:327-38.
- Epps KC, Wilensky RL. Lp-PLA (2)- a novel risk factor for highrisk coronary and carotid artery disease. *J Intern Med.* 2011; 269:94-106.
- Lin J, Zheng H, Cucchiara BL, Li J, Zhao X, et al. Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke. *Neurology.* 2015;85;18:1585-91.
- Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. *Nat Clin Pract Cardiovasc Med.* 2005;2:529-35.
- Gong H, Du Y, Zhong L, et al. Plasma Lipoprotein-associated Phospholipase A2 in Patients with Metabolic Syndrome and Carotid Atherosclerosis. *Lipids in Health and Disease.* 2011;10:13.
- Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. *Arterioscler Thromb.* 1991;11:1245-9.
- Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. *Circulation.* 1997;96:1432-7.
- Ratchford EV, Carson KA, Jones SR, et al. Usefulness of coronary and carotid imaging rather than traditional atherosclerotic risk factors to identify firefighters at increased risk for cardiovascular disease. *Am J Cardiol.* 2014;113:1499-504.
- Campo S, Sardo MA, Bitto A, Bonaiuto A, Trimarchi G, Bonaiuto M, Castaldo M, Saitta C, Cristadoro S, Saitta A: Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals. *Clin Chem.* 2004, 50:2077-2082.
- Kiortsis DN, Tsouli S, Lourida ES, Xydis V, Argyropoulou MI, Elisaf M, Tselepis AD: Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. *Angiology.* 2005;56:451-458.

**Source of Support:** Nil; **Conflict of Interest:** None

**Submitted:** 18-04-2017; **Accepted:** 23-05-2017; **Published:** 03-06-2017